An Open Label, Phase II Study of Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra (Lopinavir/Ritonavir) as Their Second Protease Inhibitor.

Criterios de inclusión

• Inclusion:
• Subject must remain on current antiretroviral therapy during screening until a new regimen is initiated.
• Subject demonstrates reduced susceptibility to lopinavir.
• Subject's two most recent viral loads obtained after at least 16 weeks of lopinavir/ritonavir therapy, and while still on Kaletra therapy must be at least 1,000 copies/mL.
• The Kaletra regimen must be the subject's second PI containing regimen and must not contain any other PIs.
• Subject is at least 18 years of age.
• Subject has not been treated for an active opportunistic infection within 30 days of screening.
• Exclusion:
• Subject has a history of active substance abuse or psychiatric illness that could preclude compliance to the protocol.
• Female subject pregnant or lactating.
• Use of an Investigational drug within 30 days prior to the initiation of drug dosing.
• Subject is receiving systemic chemotherapy.
• Subject has a history of acute or chronic pancreatitis.